CRNX Crinetics Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CRNX

Price (delayed)

$47.2

Market cap

$3.28B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.69

Enterprise value

$3.28B

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, ...

Highlights
CRNX's equity has surged by 70% year-on-year
The quick ratio has decreased by 7% QoQ but it has increased by 5% YoY
CRNX's net income is down by 31% year-on-year and by 8% since the previous quarter
The company's EPS fell by 17% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.crinetics.com
Peers: OMER OMGA

Key stats

What are the main financial stats of CRNX
Market
Shares outstanding
69.6M
Market cap
$3.28B
Enterprise value
$3.28B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
5.85
Price to sales (P/S)
683.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
817.46
Earnings
Revenue
$4.01M
EBIT
-$214.53M
EBITDA
-$212.22M
Free cash flow
-$171M
Per share
EPS
-$3.69
Free cash flow per share
-$2.94
Book value per share
$8.07
Revenue per share
$0.07
TBVPS
$10.94
Balance sheet
Total assets
$635.35M
Total liabilities
$96.25M
Debt
$51.73M
Equity
$539.11M
Working capital
$530.21M
Liquidity
Debt to equity
0.1
Current ratio
13.07
Quick ratio
12.74
Net debt/EBITDA
0.02
Margins
EBITDA margin
-5,288.3%
Gross margin
100%
Net margin
-5,345.9%
Operating margin
-5,547.2%
Efficiency
Return on assets
-45.5%
Return on equity
-52.9%
Return on invested capital
-54.8%
Return on capital employed
-36.3%
Return on sales
-5,345.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRNX stock price

How has the Crinetics Pharmaceuticals stock price performed over time
Intraday
0.9%
1 week
12.06%
1 month
-0.88%
1 year
118.82%
YTD
32.66%
QTD
0.83%

Financial performance

How have Crinetics Pharmaceuticals's revenue and profit performed over time
Revenue
$4.01M
Gross profit
$4.01M
Operating income
-$222.61M
Net income
-$214.53M
Gross margin
100%
Net margin
-5,345.9%
The operating margin has plunged by 57% YoY and by 26% from the previous quarter
The net margin has dropped by 54% year-on-year and by 27% since the previous quarter
CRNX's operating income is down by 33% YoY and by 7% from the previous quarter
CRNX's net income is down by 31% year-on-year and by 8% since the previous quarter

Growth

What is Crinetics Pharmaceuticals's growth rate over time

Valuation

What is Crinetics Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.85
P/S
683.02
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
817.46
The company's EPS fell by 17% YoY
CRNX's P/B is 72% above its 5-year quarterly average of 3.4 and 63% above its last 4 quarters average of 3.6
CRNX's equity has surged by 70% year-on-year
The P/S is 114% above the last 4 quarters average of 319.3 but 13% below the 5-year quarterly average of 788.9
The revenue is down by 15% year-on-year and by 15% since the previous quarter

Efficiency

How efficient is Crinetics Pharmaceuticals business performance
The company's return on sales has shrunk by 54% YoY and by 27% QoQ
The return on invested capital rose by 13% since the previous quarter and by 6% year-on-year
The company's return on equity fell by 10% YoY but it rose by 7% QoQ
The ROA has increased by 9% from the previous quarter but it has decreased by 3.6% YoY

Dividends

What is CRNX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRNX.

Financial health

How did Crinetics Pharmaceuticals financials performed over time
The total liabilities has soared by 168% YoY and by 2.6% from the previous quarter
The total assets has surged by 80% year-on-year
The debt is 90% smaller than the equity
CRNX's equity has surged by 70% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.